Columbia University researchers have developed a novel technique to regenerate damaged heart tissue using extracellular vesicles secreted by cardiomyocytes. The findings, reported in the journal Nature Biomedical Engineering, could help scientists develop new treatments for cardiac medical conditions.
$256,206 in average annual savings The Verax Platelet PGD test improves platelet safety, extends shelf life, and protects your bottom line. PGD users who extend platelet dating to seven days save an average of more than $250,000 a year. Maybe it's time for you to join them. Learn more.
An early-stage study was launched by researchers at the University of Massachusetts to assess the safety of a potential vaccine for HIV. The clinical trial, which will take place at four sites, will include one group of patients that will receive the priming-booster regimen and another group that will get the DNA vaccine and the protein vaccine simultaneously.
Magellan Health's pharmacy benefit management division Magellan Rx reported that its hemophilia management program has resulted in reduced potential waste, with no reports of breakthrough bleeding among patients who had dose reductions.
Autolus acquired worldwide rights to develop and commercialize UCL Business' AUTO1, a CD19 chimeric antigen receptor T-cell therapy to treat B-cell malignancies. The drug candidate is being evaluated in early-stage studies for acute lymphoblastic leukemia in children and adults.
Enlivex Therapeutics, which is working on a treatment for graft-versus-host disease, signed a nonbinding memorandum of understanding with Korea Investment Partners for a $2 million investment. Enlivex shareholder Hadasit Bio-Holdings will also invest $1.2 million as part of the agreement, and both parties will recruit other investors to complete a funding round of $6 million to $10 million.
A new-drug application was submitted to the FDA by Astellas Pharma for its Gilteritinib, which is being developed as a treatment for patients with FLT3MUT+ relapsed or refractory acute myeloid leukemia.
Pfizer's Mylotarg, or gemtuzumab ozogamicin, was approved in combination with chemotherapy agents daunorubicin and cytarabine by the European Commission as a treatment for patients at least 15 years old who have previously untreated de novo CD33-positive acute myeloid leukemia.